This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
RETACRIT® (epoetin alfa-epbx) is a biosimilar to Epogen®/Procrit® (epoetin alfa) and part of the largest oncology biosimilars portfolio, brought to you by Pfizer
RETACRIT® (epoetin alfa-epbx) is a biosimilar to Epogen®/Procrit® (epoetin alfa) and part of the largest oncology biosimilars portfolio, brought to you by Pfizer
With an identical dosing and administration schedule to Epogen®/Procrit®1
Downloadable resources to help support your implementation of RETACRIT
With 15+ years of biosimilars experience globally, including more than 1.3 million people treated around the world2,5
View reimbursement, educational, and patient materials
Find videos and on-demand webinars
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.
WARNINGS: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
CHRONIC KIDNEY DISEASE
CANCER
PERISURGERY
CONTRAINDICATIONS
RETACRIT® is contraindicated in patients with:
RETACRIT® from multiple-dose vials contains benzyl alcohol and is contraindicated in:
INCREASED MORTALITY, MYOCARDIAL INFARCTION, STROKE, AND THROMBOEMBOLISM
INCREASED MORTALITY AND/OR INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE IN PATIENTS WITH CANCER
HYPERTENSION
SEIZURES
LACK OR LOSS OF HEMOGLOBIN RESPONSE TO RETACRIT®
PURE RED CELL APLASIA
SERIOUS ALLERGIC REACTIONS
SEVERE CUTANEOUS REACTIONS
RISK OF SERIOUS ADVERSE REACTIONS DUE TO BENZYL ALCOHOL PRESERVATIVE
RISK IN PATIENTS WITH PHENYLKETONURIA
DIALYSIS MANAGEMENT
ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE
ANEMIA DUE TO CHEMOTHERAPY IN PATIENTS WITH CANCER
SURGERY/PERISURGERY
ANEMIA DUE TO ZIDOVUDINE IN PATIENTS WITH HIV INFECTION